North Carolina Hematologic Malignancies Symposium 2026: Evidence-Based Updates and Clinical Decision-Making in Lymphoma, CLL, Myeloma, AML, and MPNs
Venue: Washington Duke Inn & Golf Club, 3001 Cameron Blvd, Durham, NC, 27705, United States
Official conference page for North Carolina Hematologic Malignancies Symposium 2026: Evidence-Based Updates and Clinical Decision-Making in Lymphoma, CLL, Myeloma, AML, and MPNs. https://binaytara.org/projects/conferences/north-carolina-hematologic-malignancies-symposium
About North Carolina Hematologic Malignancies Symposium 2026: Evidence-Based Updates and Clinical Decision-Making in Lymphoma, CLL, Myeloma, AML, and MPNs
Faculty and committee
Conference program and agenda
Agenda
Friday, October 16th, 2026
All timings are in Eastern Time (EDT, GMT-04:00) time.
Session Chair: Nilanjan Ghosh, MD, PhD
08:50 AM - 09:00 AM
Treatment of Relapsed or Refractory Marginal Zone Lymphoma – Rakhee Vaidya, MD
09:00 AM - 09:10 AM
Second Line Treatment of Diffuse Large B-cell Lymphoma
09:10 AM - 09:20 AM
Treatment of Relapsed or Refractory Follicular Lymphoma – Matthew McKinney, MD
09:25 AM - 09:35 AM
Panel Discussion
Moderators:
Nilanjan Ghosh, MD, PhD
Panelists:
Matthew McKinney, MD
Session Chair: Debbie Stephens, DO
09:45 AM - 09:55 AM
Should we use Pirtobrutinib in Frontline Treatment of CLL? – Andrea Sitlinger, MD
09:55 AM - 10:05 AM
When should we use PVR for relapsed/refractory CLL? – Ryan W Jacobs, MD
10:05 AM - 10:15 AM
When should we use MRD to guide therapy for CLL?
10:15 AM - 10:30 AM
Panel Discussion
Moderators:
Debbie Stephens, DO
Panelists:
Andrea Sitlinger, MD; Ryan W Jacobs, MD
Session Chair: Sascha Tuchman, MD
10:30 AM - 10:40 AM
What's the real role for plasma exchange in cast nephropathy? – Cristiana Costa
10:40 AM - 10:50 AM
Who with myeloma really needs IVIG? – Eben Lichtman
10:50 AM - 11:00 AM
What's the optimal way to treat bone disease and enhance bone health in myeloma? – Franklin Chen, MD
11:00 AM - 11:15 AM
Panel Discussion
Moderators:
Sascha Tuchman, MD
Panelists:
Cristiana Costa ; Eben Lichtman ; Franklin Chen, MD
Session Chair: Joshua Zeidner
12:15 PM - 12:23 PM
Debate: HMA/Venetoclax is the new standard of care for newly diagnosed AML patients irrespective of age (Pro) – Lacey Williams, MD
12:23 PM - 12:31 PM
Debate: HMA/Venetoclax is the new standard of care for newly diagnosed AML patients irrespective of age (Con) – Madeleine Burkheart
12:31 PM - 12:39 PM
Debate: HMA/Venetoclax Triplets will be the standard of care for all older AML patients in the future? (Pro) – Daniel Peters, MD
12:39 PM - 12:47 PM
Debate: HMA/Venetoclax Triplets will be the standard of care for all older AML patients in the future? (Con) – Thomas LeBlanc, MD
12:47 PM - 01:00 PM
Panel Discussion
Moderators:
Joshua Zeidner
Panelists:
Lacey Williams, MD; Daniel Peters, MD; Thomas LeBlanc, MD; Madeleine Burkheart
Session Chair: Lindsay Rein, MD